219 related articles for article (PubMed ID: 2469101)
1. The PGI2-analogue iloprost and the TXA2-receptor antagonist sulotroban synergistically inhibit TXA2-dependent platelet activation.
Stürzebecher S; Witt W
Prostaglandins; 1988 Dec; 36(6):751-60. PubMed ID: 2469101
[TBL] [Abstract][Full Text] [Related]
2. Synergistic antiplatelet and antithrombotic effects of a prostacyclin analogue (iloprost) combined with a thromboxane antagonist (sulotroban) in guinea pigs and rats.
Witt W; Stürzebecher S; Müller B
Thromb Res; 1988 Sep; 51(6):607-16. PubMed ID: 2460967
[TBL] [Abstract][Full Text] [Related]
3. Antiplatelet effects of the novel thromboxane A2 receptor antagonist sodium (E)-11-[2-(5,6-dimethyl-1-benzimidazolyl)-ethylidene]-6,11- dihydrodibenz[b,e] oxepine-2-carboxylate monohydrate.
Karasawa A; Kawakage M; Shirakura S; Higo K; Kubo K; Ohshima E; Obase H
Arzneimittelforschung; 1991 Dec; 41(12):1230-6. PubMed ID: 1840011
[TBL] [Abstract][Full Text] [Related]
4. Thromboxane (Tx) A2 receptor blockade and TxA2 synthase inhibition alone and in combination: comparison of anti-aggregatory efficacy in human platelets.
Watts IS; Wharton KA; White BP; Lumley P
Br J Pharmacol; 1991 Feb; 102(2):497-505. PubMed ID: 1826620
[TBL] [Abstract][Full Text] [Related]
5. Competitive antagonism at thromboxane receptors in human platelets.
Armstrong RA; Jones RL; Peesapati V; Will SG; Wilson NH
Br J Pharmacol; 1985 Mar; 84(3):595-607. PubMed ID: 2580580
[TBL] [Abstract][Full Text] [Related]
6. Intrinsic activity of the non-prostanoid thromboxane A2 receptor antagonist, daltroban (BM 13,505), in human platelets in vitro and in the rat vasculature in vivo.
Bertolino F; Valentin JP; Maffre M; Grelac F; Bessac AM; Maclouf J; Delhon A; Lévy-Toledano S; Patoiseau JF; Colpaert FC
Br J Pharmacol; 1995 May; 115(1):210-6. PubMed ID: 7647979
[TBL] [Abstract][Full Text] [Related]
7. Platelet endoperoxide/thromboxane A2 (PGH2/TXA2) receptors in patients with myeloproliferative disorders.
Faul C; Renn W; Jaschonek K
Prostaglandins Leukot Essent Fatty Acids; 1991 Aug; 43(4):273-6. PubMed ID: 1835097
[TBL] [Abstract][Full Text] [Related]
8. Irreversible inhibition of the TXA2/PGH2 receptor of human platelets by a photoaffinity ligand.
Zehender H; Witte EC; Wolff HP; Patscheke H
Biochem Pharmacol; 1988 Feb; 37(3):491-5. PubMed ID: 2962585
[TBL] [Abstract][Full Text] [Related]
9. Labeling of human platelet plasma membrane thromboxane A2/prostaglandin H2 receptors using SQB, a novel biotinylated receptor probe.
Komiotis D; Wencel-Drake JD; Dieter JP; Lim CT; Le Breton GC
Biochem Pharmacol; 1996 Sep; 52(5):763-70. PubMed ID: 8765474
[TBL] [Abstract][Full Text] [Related]
10. Thromboxane A2 receptor antagonism in man and rat by a sulphonylcyanoguanidine (BM-144) and a sulphonylurea (BM-500).
Masereel B; Damas J; Fontaine J; Lembege M; Lacan F; Nuhrich A; Delarge J; Pochet L; Dogne JM
J Pharm Pharmacol; 1999 Jun; 51(6):695-701. PubMed ID: 10454046
[TBL] [Abstract][Full Text] [Related]
11. Antiaggregatory effects of thromboxane receptor antagonists in vivo.
Darius H; Lefer AM
Thromb Res; 1985 Dec; 40(5):663-75. PubMed ID: 2935972
[TBL] [Abstract][Full Text] [Related]
12. Homologous desensitization of human platelet thromboxane A2/prostaglandin H2 receptors.
Okwu AK; Ullian ME; Halushka PV
J Pharmacol Exp Ther; 1992 Jul; 262(1):238-45. PubMed ID: 1378092
[TBL] [Abstract][Full Text] [Related]
13. Potentiation by dazoxiben, a thromboxane synthetase inhibitor, of platelet aggregation inhibitory activity of a thromboxane receptor antagonist and of prostacyclin.
Bertele V; De Gaetano G
Eur J Pharmacol; 1982 Dec; 85(3-4):331-3. PubMed ID: 6295787
[TBL] [Abstract][Full Text] [Related]
14. [Effect of a new thromboxane A2 antagonist, S-145, on platelet aggregation].
Kakushi H; Shike T; Uchida K
Nihon Yakurigaku Zasshi; 1989 Mar; 93(3):171-8. PubMed ID: 2731807
[TBL] [Abstract][Full Text] [Related]
15. Pharmacological characterization of potent, long-acting thromboxane receptor antagonists, SQ 33,261 and SQ 33,552.
Harris DN; Michel IM; Goldenberg HJ; Hartl KS; Allen GT; Steinbacher TE; Schumacher WA; Han WC; Hall SE; Floyd DM
J Pharmacol Exp Ther; 1992 Apr; 261(1):131-7. PubMed ID: 1532833
[TBL] [Abstract][Full Text] [Related]
16. Prostacyclin potentiates 13-azaprostanoic acid-induced platelet deaggregation.
Parise LV; Venton DL; Le Breton GC
Thromb Res; 1982 Dec; 28(6):721-30. PubMed ID: 6301090
[TBL] [Abstract][Full Text] [Related]
17. Antiaggregatory activity of 8-epi-prostaglandin F2 alpha and other F-series prostanoids and their binding to thromboxane A2/prostaglandin H2 receptors in human platelets.
Yin K; Halushka PV; Yan YT; Wong PY
J Pharmacol Exp Ther; 1994 Sep; 270(3):1192-6. PubMed ID: 7932171
[TBL] [Abstract][Full Text] [Related]
18. Prostaglandin endoperoxide analogues which are both thromboxane receptor antagonists and prostacyclin mimetics.
Armstrong RA; Jones RL; MacDermot J; Wilson NH
Br J Pharmacol; 1986 Mar; 87(3):543-51. PubMed ID: 3026540
[TBL] [Abstract][Full Text] [Related]
19. Effects of endogenous and synthetic prostanoids, the thromboxane A2 receptor agonist U-46619 and arachidonic acid on [3H]-noradrenaline release and vascular tone in rat isolated kidney.
Rump LC; Schollmeyer P
Br J Pharmacol; 1989 Jul; 97(3):819-28. PubMed ID: 2503228
[TBL] [Abstract][Full Text] [Related]
20. Agonist-induced phosphorylation of human platelet TXA2/PGH2 receptors.
Okwu AK; Mais DE; Halushka PV
Biochim Biophys Acta; 1994 Mar; 1221(1):83-8. PubMed ID: 8130280
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
